IP Library Assignment 074976/0089
Patent Assignment
Reel/Frame 074976/0089

Security Interest

Recorded: 2026-02-25 Pages: 16
Assignor
NOVAVAX, INC.
Executed: 2026-02-25
Assignee
MIDCAP FINANCIAL TRUST
7255 WOODMONT AVE, SUITE 300, BETHESDA, MARYLAND, 20814
Covered Properties (68)
Functional Influenza Virus-Like Particles (Vlps)
Patent: 7,763,450 →
Application: 11/372,466 →
Publication: US 2006/0263804
Functional Influenza Virus Like Particles (Vlps)
Patent: 8,080,255 →
Application: 11/582,540 →
Publication: US 2007/0184526
Novel Vlps Derived from Cells That Do Not Express a Viral Matrix or Core Protein
Patent: 8,697,088 →
Application: 12/127,625 →
Publication: US 2009/0017066
Functional Influenza Virus Like Particles (Vlps)
Patent: 8,506,967 →
Application: 12/340,186 →
Publication: US 2010/0129401
Functional Influenza Virus Like Particles (Vlps)
Patent: 9,050,290 →
Application: 13/890,711 →
Publication: US 2013/0295135
Modified Rsv F Proteins and Methods of Their Use
Patent: 8,715,692 →
Application: 12/633,995 →
Publication: US 2010/0239617
Avian Influenza Chimeric Vlps
Patent: 8,551,756 →
Application: 12/689,826 →
Publication: US 2010/0184192
Virus-Like Particles Comprising Chimeric Human Immunodeficiency Virus (Hiv)/Mouse Mammary Tumor Virus (Mmtv) Envelopes.
Patent: 8,795,682 →
Application: 12/598,271 →
Publication: US 2010/0196419
Highly Efficient Influenza Matrix (M1) Proteins
Patent: 8,992,939 →
Application: 13/280,043 →
Publication: US 2013/0039938
Rabies Glycoprotein Virus-Like Particles (Vlps)
Patent: 9,724,405 →
Application: 13/883,745 →
Publication: US 2014/0178419
Functional Influenza Virus-Like Particles (Vlps)
Patent: 8,951,537 →
Application: 13/297,125 →
Publication: US 2012/0207786
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,144,607 →
Application: 13/796,125 →
Publication: US 2013/0177587
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,180,180 →
Application: 14/149,365 →
Publication: US 2014/0193447
Modified Rsv F Proteins and Methods of Their Use
Patent: 9,675,685 →
Application: 14/221,675 →
Publication: US 2014/0294879
Novel Vlps Derived from Cells That Do Not Express a Viral Matrix or Core Protein
Patent: 9,381,239 →
Application: 14/252,043 →
Publication: US 2014/0234372
Immunogenic Middle East Respiratory Syndrome Coronavirus (Mers-Cov) Compositions and Methods
Application: 15/023,629 →
Publication: US 2016/0206729
Highly Efficient Influenza Matrix (M1) Proteins
Patent: 9,464,276 →
Application: 14/628,513 →
Publication: US 2015/0307849
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,474,799 →
Application: 14/700,577 →
Publication: US 2015/0306206
Modified Rsv F Proteins and Methods of Their Use
Patent: 9,731,000 →
Application: 14/730,805 →
Publication: US 2015/0265698
Modified Rsv F Proteins and Methods of Their Use
Patent: 9,717,786 →
Application: 14/730,809 →
Publication: US 2015/0266930
Functional Influenza Virus Like Particles (Vlps)
Patent: 9,694,066 →
Application: 14/733,632 →
Publication: US 2015/0374813
Modified Rsv F Proteins and Methods of Their Use
Application: 14/839,247 →
Publication: US 2015/0359872
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,623,104 →
Application: 14/869,039 →
Publication: US 2016/0008456
Vaccine Compositions Having Improved Stability and Immunogenicity
Application: 15/257,436 →
Publication: US 2017/0202948
Highly Efficient Influenza Matrix (M1) Proteins
Patent: 9,951,317 →
Application: 15/287,433 →
Publication: US 2017/0253861
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,956,280 →
Application: 15/332,330 →
Publication: US 2017/0232095
Functional Influenza Virus-Like Particles (Vlps)
Patent: 9,937,253 →
Application: 15/454,820 →
Publication: US 2017/0252427
Functional Influenza Virus Like Particles (Vlps)
Application: 15/608,532 →
Publication: US 2018/0110851
Rabies Glycoprotein Virus-Like Particles (Vlps)
Application: 15/638,955 →
Publication: US 2018/0021428
Vaccine Compositions Having Improved Stability and Immunogenicity
Application: 15/819,962 →
Publication: US 2018/0133308
Functional Influenza Virus-Like Particles (Vlps)
Application: 15/901,000 →
Publication: US 2019/0038738
Methods and Compositions for Inducing Immune Responses Against Clostridium Difficile
Application: 16/494,517 →
Publication: US 2020/0085934
Highly Efficient Influenza Matrix (M1) Proteins
Application: 15/928,385 →
Publication: US 2019/0062713
Modified Rsv F Proteins and Methods of Their Use
Application: 16/009,257 →
Publication: US 2019/0134187
Functional Influenza Virus Like Particles (Vlps)
Application: 16/210,501 →
Publication: US 2019/0314484
Multivalent Influenza Nanoparticle Vaccines
Application: 16/357,876 →
Publication: US 2019/0314487
Vaccine Compositions Having Improved Stability and Immunogenicity
Application: 16/545,424 →
Publication: US 2020/0101151
Modified Rsv F Proteins and Methods of Their Use
Application: 16/599,568 →
Publication: US 2020/0030436
Methods for Preventing Disease or Disorder Caused by Rsv Infection
Application: 17/433,732 →
Publication: US 2022/0133875
Coronavirus Vaccine Formulations
Application: 16/997,001 →
Coronavirus Vaccine Formulations
Application: 17/795,337 →
Publication: US 2023/0070886
Coronavirus Vaccine Formulations
Application: 17/170,367 →
Publication: US 2021/0228708
Coronavirus Vaccine Formulations
Application: 17/205,990 →
Publication: US 2021/0228709
Methods and Compositions for Treating Respiratory Disease
Application: 16/629,859 →
Publication: US 2021/0137845
Methods and Compositions for Inducing Immune Responses Against Clostridium Difficile
Application: 17/398,610 →
Publication: US 2022/0211834
Multivalent Influenza Nanoparticle Vaccines
Application: 17/534,659 →
Publication: US 2022/0080039
Coronavirus Vaccine Formulations
Application: 17/572,182 →
Publication: US 2022/0125914
Coronavirus Vaccine Formulations
Application: 17/700,945 →
Publication: US 2022/0332765
Coronavirus and Influenza Compositions and Methods for Using Them
Application: 17/736,452 →
Publication: US 2022/0354944
Vaccine Compositions Having Improved Stability and Immunogenicity
Application: 17/750,612 →
Publication: US 2022/0387579
Modified Rsv F Proteins and Methods of Their Use
Application: 17/818,887 →
Publication: US 2023/0293667
Malaria Vaccine Formulations
Application: 18/704,632 →
Publication: US 2024/0415947
Methods and Compositions for Treating and Preventing Malaria
Application: 18/712,227 →
Publication: US 2024/0408187
Coronavirus Vaccine Formulations
Application: 18/715,010 →
Publication: US 2025/0025549
Coronavirus Vaccine Formulations
Application: 18/061,831 →
Publication: US 2023/0330216
Anti-Sars-Cov-2 Spike (S) Antibodies and Their Use in Treating Covid-19
Application: 18/723,454 →
Publication: US 2025/0066456
Downstream Process for Purification of Viral Proteins with Hydrophobic Membrane Domain for Use in Vaccine Compositions
Application: 18/458,789 →
Publication: US 2024/0076320
Coronavirus Vaccine Formulations
Application: 18/526,015 →
Publication: US 2024/0165221
Coronavirus and Influenza Compositions and Methods for Using Them
Application: 18/626,201 →
Publication: US 2024/0325523
Sars-Cov-2 Vaccine Compositions
Application: 18/645,259 →
Publication: US 2024/0374712
Methods and Compositions for Treating Respiratory Disease
Application: 18/828,852 →
Publication: US 2024/0423926
Method for Detecting Anti-Sars-Cov-2 Spike (S) Immunoglobulins
Application: 18/882,452 →
Publication: US 2025/0085282
Anti-Sars-Cov-2 Spike (S) Antibodies and Their Use in Treating Covid-19
Application: 18/900,674 →
Publication: US 2025/0109187
Compositions and Methods for Inducing an Immune Response Against Epstein-Barr Virus
Application: 18/853,030 →
Publication: US 2025/0325646
Intranasal Immunogenic Compositions
Application: 18/939,463 →
Publication: US 2025/0144200
Pseudovirus Based Neutralization Assay for Evaluating Vaccine Immunogenicity
Application: 18/998,469 →
Publication: US 2026/0028644
ACE2 Inhibition Assay for Evaluation of Vaccine Immunogenicity
Application: 18/998,471 →
Avian Influenza Nanoparticle Immunogenic Compositions
Application: 19/070,329 →
Publication: US 2025/0276054
Related Assignments (21)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Apr 3, 2007
From: SMITH, GALE; BRIGHT, RICH; PUSHKO, PETER; ZHANG, JINYOU
To: NOVARVAX, INC.
Reel/Frame 019139/0464 →
Corrective Assignment to Correct the Assignor #2: Rick Bright and Assignee: Novavax, Inc. Previously Recorded on Reel 019139 Frame 0464. Assignor(S) Hereby Confirms the Assignor #2 from <Rich> Bright to <Rick> Bright and Receiving Party from <Novarvax>, Inc. to <Novavax>, Inc.. May 9, 2007
From: SMITH, GALE; BRIGHT, RICK; PUSHKO, PETER; ZHANG, JINYOU
To: NOVAVAX, INC.
Reel/Frame 019267/0668 →
Assignment of Assignor's Interest Apr 4, 2008
From: ROBINSON, ROBIN A.; PUSHKO, PETER M.
To: NOVAVAX, INC.
Reel/Frame 020756/0793 →
Assignment of Assignor's Interest Aug 27, 2009
From: SMITH, GALE; PUSHKO, PETER; MAHMOOD, KUTUB; ZHOU, BIN
To: NOVAVAX, INC.
Reel/Frame 023156/0856 →
Assignment of Assignor's Interest Mar 25, 2010
From: SMITH, GALE; PUSHKO, PETER
To: NOVAVAX, INC.
Reel/Frame 024134/0286 →
Assignment of Assignor's Interest Mar 31, 2010
From: COMPANS, RICHARD W.; WANG, BAOZHONG
To: EMORY UNIVERSITY
Reel/Frame 024166/0766 →
Assignment of Assignor's Interest Mar 31, 2010
From: HAHN, BEATRICE; LIU, WEIMIN
To: UNIVERSITY OF ALABAMA
Reel/Frame 024166/0971 →
Assignment of Assignor's Interest Mar 31, 2010
From: SMITH, GALE; PUSHKO, PETER
To: NOVAVAX, INC.
Reel/Frame 024166/0796 →
Assignment of Assignor's Interest Jun 7, 2010
From: PUSHKO, PETER; WU, YINGYUN; MASSARE, MICHAEL; LIU, YE
To: NOVAVAX, INC.
Reel/Frame 024494/0933 →
Assignment of Assignor's Interest Apr 24, 2012
From: SMITH, GALE; BRIGHT, RICK; PUSHKO, PETER M.; ZHANG, JINYOU
To: NOVAVAX, INC.
Reel/Frame 028098/0135 →
Assignment of Assignor's Interest May 15, 2012
From: SMITH, GALE; BRIGHT, RICK; PUSHKO, PETER; ZHANG, JINYOU
To: NOVAVAX, INC.
Reel/Frame 028209/0223 →
Assignment of Assignor's Interest Aug 1, 2012
From: HAHN, BEATRICE; LIU, WEIMIN
To: THE UAB RESEARCH FOUNDATION
Reel/Frame 028695/0175 →
Assignment of Assignor's Interest Jan 23, 2013
From: SMITH, GALE; WU, YINGYUN; MASSARE, MICHAEL; PUSHKO, PETER
To: NOVAVAX INC.
Reel/Frame 029677/0032 →
Assignment of Assignor's Interest Oct 28, 2013
From: SMITH, GALE; BRIGHT, RICK; PUSHKO, PETER M.; ZHANG, JINYOU
To: NOVAVAX, INC.
Reel/Frame 031491/0976 →
Assignment of Assignor's Interest Oct 28, 2013
From: SMITH, GALE; LIU, YE
To: NOVAVAX, INC.
Reel/Frame 031491/0897 →
Assignment of Assignor's Interest Oct 28, 2013
From: ROBINSON, ROBIN A.; PUSHKO, PETER M.
To: NOVAVAX, INC.
Reel/Frame 031491/0718 →
Assignment of Assignor's Interest Feb 9, 2015
From: SMITH, GALE; PUSHKO, PETER; MAHMOOD, KUTUB; ZHOU, BIN
To: NOVAVAX, INC.
Reel/Frame 034920/0608 →
Assignment of Assignor's Interest Feb 9, 2015
From: PUSHKO, PETER; WU, YINGYUN; MASSARE, MICHAEL; LIU, YE
To: NOVAVAX, INC.
Reel/Frame 034920/0468 →
Assignment of Assignor's Interest Apr 2, 2015
From: SMITH, GALE; BRIGHT, RICK; PUSHKO, PETER; ZHANG, JINYOU
To: NOVAVAX, INC.
Reel/Frame 035318/0279 →
Assignment of Assignor's Interest Aug 6, 2015
From: SMITH, GALE; WU, YINGYUN; MASSARE, MICHAEL; PUSHKO, PETER
To: NOVAVAX, INC.
Reel/Frame 036271/0729 →
Assignment of Assignor's Interest Aug 2, 2016
From: SMITH, GALE; LIU, YE; MASSARE, MICHAEL
To: NOVAVAX, INC.
Reel/Frame 039319/0754 →